Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Medline Inc. Class A Common Stock (MDLN) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Medline Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Medline Inc. Class A Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.91 (market cap $772.39M), while Medline Inc. Class A Common Stock trades at $35.74 (market cap $31.10B). The key difference: Medline Inc. Class A Common Stock is far larger — about 40.3× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Medline Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Medline Inc. Class A Common Stock for 0 Days on average.

DNAMDLN
Market Cap
$772.39M$31.10B
Volume
6,453,2734,471,639
Sector
HealthHealth
52-Week High
$15.83$49.99
52-Week Low
$5.48$31.64
Typical Hold Time
7 Days0 Days
Enterprise Value
$874.34M$41.07B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.

The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.

Medline Inc. Class A Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
53% Buy47% Sell
Avg holding period · 7 Days
MDLN
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About Medline Inc. Class A Common Stock

Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.

Read more on MDLN →